Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study

Documenti analoghi

• NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort
  di: Calogero Vetro, et al.
  Pubblicazione: (2026)
• Impact of Pre‐Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents
  di: Giovanni Marconi, et al.
  Pubblicazione: (2025)
• Theory and applications of the Sum-Of-Squares technique
  di: Bach, Francis, et al.
  Pubblicazione: (2023)
• High order Tensor-Train-Based Schemes for High-Dimensional Mean Field Games
  di: Carlini, Elisabetta, et al.
  Pubblicazione: (2025)
• Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting
  di: Jacopo Nanni, et al.
  Pubblicazione: (2025)